Piperidine derivatives as liver X receptor beta agonists, compositions, and their use

US10894775B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Michael T. Rudd · Collegeville, US
• Zhaoyang Meng · Ambler, US
• Jenny Wai · Harleysville, US
• David Jonathan Bennett · Watertown, US
• Edward J. Brnardic · Lansdale, US
• Nigel J. Liverton · Harleysville, US
• Shawn J. Stachel · Perkasie, US
• Yongxin Han · Kirkland, CA
• Paul Tempest · Brookline, US
• Jiuxiang Zhu · Shanghai, CN
• Xuewang Xu · Shanghai, CN
• Bin Zhu · Spring House, US
• Chuanman Huang · Shanghai, CN

Key dates

• Filing date: Oct 9, 2017
• Grant date: Jan 19, 2021
• Expiry date: Oct 9, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.